JCL Bioassay Corporation (JCL Bioassay) is a Japan based company, engaged in contract testing and research related to drug development. The company operates through one business segment that provides bioanalysis, and stability testing of drug quality. Its activities include development of bioanalytical methods, such as high-performance liquid chromatography (HPLC), and high performance liquid chromatography tandem mass spectrometry (LC-MS/MS). JCL Bioassay is engaged in the structural analysis and testing of metabolite in the nonclinial and clinical period. Through its bio analysis, it measures the drug concentration of biological samples, as well as the medicine quality stability testing. Recently, the company established JCL Bioassay USA, Inc., to provide testing and research services. The services offered by the company includes structure determination in vivo metabolites in phase I clinical study; structure determination of metabolites produced by in vitro metabolic experiment; metabolome research of biomarker relating pharmacology and toxicology; structure determination of in vivo metabolites in toxicological study; and contract study on proteome. The company is headquartered in Osaka, Japan.The company reported revenues of (Yen) JPY 2,488.48 million during the fiscal year ended March 2009, an increase of 6.96% over 2008. The operating profit of the company was JPY 502.84 million during the fiscal year 2009, an increase of 40.65% over 2008. The net profit of the company was JPY 259.11 million during the fiscal year 2009, an increase of 11.27% over 2008.